Fig. 1
LncRNA AGAP2-AS1 is upregulated and induced by SP1 in breast cancer cells. a RT-qPCR was performed to detect the expression level of AGAP2-AS1 in breast cancer cells. b The IC50 value of trastuzumab was detected for both sensitive and resistant cells by cell viability assay. c The cell viability of both trastuzumab-resistant and sensitive cells were determined. d AGAP2-AS1 expression was identified by RT-qPCR in both trastuzumab-resistant and sensitive cells. e Prediction of SP1 binding site in the AGAP2-AS1 promoter region using JASPAR (http://jaspar.genereg.net/). f The expression of SP1 in gefitinib resistant and parental cells at transcript (left panel) and protein (right panel) levels. g RT-qPCR analysis of AGAP2-AS1 expression after SP1 was overexpressed. h FISH analysis of the enriched level of SP1 gene in nucleus of the SKBR-3 or SKBR-3/Tr cells. i ChIP assay was performed to detect the relative enrichment of SP1 in promoter of AGAP2-AS1. j Schematic presentation of SP1 binding sites in the promoter region of AGAP2-AS1. k Luciferase activity analysis of the two binding sites in cells transfected with respective oligonucleotides. *p < 0.05, **p < 0.01, ***p < 0.001